Alzheimer's Drug Discovery Foundation

The Alzheimer's Drug Discovery Foundation (ADDF) operates as a unique venture philanthropy organization, singularly focused on accelerating the discovery and development of drugs to prevent, treat, and cure Alzheimer's disease. Based in New York, the ADDF employs a rigorous scientific review process to identify and fund the most promising, innovative research worldwide, bridging the critical funding gap between basic scientific discoveries and large-scale pharmaceutical development. Their strategic approach emphasizes de-risking early-stage drug candidates, making them more attractive for subsequent private investment and clinical trials.

ADDF's investment strategy is highly targeted, prioritizing novel drug targets and therapeutic approaches that address the complex pathology of Alzheimer's. They fund a diverse pipeline of programs, including those focused on inflammation, epigenetics, mitochondrial dysfunction, and the development of biomarkers crucial for early diagnosis and monitoring treatment efficacy. The foundation provides critical seed and early-stage funding to both academic institutions and biotechnology companies globally, enabling the translation of cutting-edge research into potential therapies. This focused model allows them to support high-risk, high-reward projects that might otherwise struggle to secure traditional venture capital.

Since its inception, the ADDF has demonstrated a significant commitment to combating Alzheimer's, having awarded over $275 million to fund more than 720 drug discovery programs. Their typical initial grants, or "first cheques," are designed to provide substantial support for preclinical and early-phase clinical development. While specific grant sizes vary based on the program's stage and needs, initial commitments generally range from $250,000 for highly focused early-stage target validation up to $1,500,000 for more advanced preclinical or initial clinical trial support. This strategic deployment of capital aims to advance a diverse portfolio of potential treatments towards human trials, ultimately striving to bring effective therapies to patients faster.